Karen Hale, who joined Novartis in 2021 as chief legal officer, will take on the new chief legal and compliance officer role.

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced the appointment of Celine ...

French biotech Transgene (EPA: TNG) has named Simone Steiner as its new chief technical officer, in a move aimed at advancing ...

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

Docquity, Southeast Asia's largest network of healthcare professionals (HCPs), and global healthcare company Novartis announce a multi-year partnership in Malaysia to address the rise of retinal ...

Novartis signed on for its space at the Fifth Avenue building between West 39th and West 40th streets in January 2023, as Commercial Observer previously reported. It represented the company’s first ...